45results about How to "Increased cell yield" patented technology

The subject invention provides materials and methods wherein unique and advantageous combinations of gene mutations are used to direct carbon flow from sugars to a single product. The techniques of the subject invention can be used to obtain products from native pathways as well as from recombinant pathways. In preferred embodiments, the subject invention provides new materials and methods for the efficient production of acetate and pyruvic acid.

The present invention discloses a three-dimensional porous growth surface made from polysaccharide material, especially the alginic acid, to enhance cell growth surface, promote cell adherence, immobilization and propagation, maintain surface structure integrity, enable programmable degradation, and thus increase cellular production. The present invention teaches several methods: a method to enhance the integrity of the growth surface by protecting the growth surface in a rigid solid support; a method of use for enhancing the performance of the surface; and a method of modifying a growth surface for eukaryotic and/or prokaryotic cells comprising the steps of increasing surface area by creating porous and 3-D structure, treating a surface to encourage cell attachment, promoting cell growth and proliferation, and disposing the growth surface in any conventional cell cultivating device. The growth surface is able to program degradation and release the cell/tissue mass after the culture is completed.

A method of isolating epithelial cells from a human skin tissue or internal organ tissue using trypsin and ethylene-diamine tetraacetic acid (EDTA) simultaneously with the application of magnetic stirring, a method of preconditioning isolated biological cells by the application of physical stimulus, i.e., strain, are provided. Epithelial cells can be isolated by the method with increased yield, colony forming efficiency (CFE), and colony size. Also, the increased percentage of stem cells in isolated cells is advantageous in therapeutic tissue implantation by autologous or allogeneic transplantation. In skin cells preconditioned by the application of strain, cell division is facilitated, and the secretion of extracellular matrix components and growth factors and the activity of matrix metalloproteinases (MMPs) are improved. When preconditioned cells are implanted by autologous or allogeneic transplantation to heal a damaged tissue, the improved cell adhesion, mobility, and viability provides a biological adjustment effect against a variety of stresses or physical stimuli which the cells would undergo after implantation, with improved capability of integration into host tissue, thereby markedly improving the probability of success in skin grafting.

The present invention relates to a novel hepatocyte-like cell population derived from hBS cells and to the potential use of such heopatocyte-like cells in e.g. medical treatment, drug screening and toxicity testing. Furthermore, the invention relates to hepatoblast-like cells that may have suitable characteristics so that they can be used for the same applications as the hepatocyte-like cells and that furthermore may be used in in vitro studies of hepatogenesis such as early hepatogenesis or hepato-regenerative disorders. Both the hepatocyte-like and the hepatoblast-like cells according to the invention express drug transporter and/or drug metabolising characteristics either at the gene or protein expression level.

A method for producing an electrode catalyst substrate is provided herein, which comprises a carbon film forming step of forming a porous carbon film on a base, a hydrophilization step of hydrophilizing the porous carbon film, an immersion step of immersing the base in a solution prepared by dissolving catalytic metal ions in a polar solvent, and a reduction step of adding a reducing agent to the solution and thus reducing the catalytic metal ions. An electrode catalyst substrate obtained by the method and a polymer electrolyte fuel cell in which the electrode catalyst obtained by the method is used for anodes and/or cathodes are also provided herein. In the electrode catalyst of the present invention, fine catalyst particles are loaded in a uniform and highly dispersed manner.

In a solid oxide fuel cell, the nonuniformity of temperature distribution in the axial direction of a solid electrolyte, the decrease in cell performance caused by a decreased effective cell reaction area, and the damage to cell due to thermal stress generated by a temperature difference are restrained. A reforming catalyst is provided in a high-temperature portion on the anode side to cool the high-temperature portion by means of heat absorption of reforming reaction, or a combustion catalyst is provided in a low-temperature portion on the anode side to heat the low-temperature portion by means of heat generation of combustion reaction, or both of the catalysts are provided, by which the occurrence of variations in temperature in a cell reaction region of anode is prevented. In addition, an air flow from an air introduction tube of cathode is branchingly sprayed so that a cooling effect is produced in the high-temperature portion, by which an effect of restraining the variations in temperature can further be increased.

Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability and enhanced proliferation in culture. Stem cells of the invention retain their plasticity through a higher number of cell passages relative to know methods of stem cell culture.

Based on previous evidence suggesting positive effects of fever on in vivo hematopoiesis, the effect of hyperthermia on the expansion and differentiation of megakaryocytes (MKs) in ex vivo cultures of CB CD34-enriched cells has now been tested. Cells were cultured at 37° C. or 39° C. for 14 days in cytokine conditions optimized for MK development, and analyzed periodically by microscopy, flow cytometry and colony assays. Compared to 37° C., cultures maintained at 39° C. produced much more total cells (5X), MK progenitors (9X) and total MKs (7X), and showed accelerated (3-4 days) and enhanced MK maturation with increased yields of proplatelets and platelets (11.7X). The increased number of CD34+ cells and myeloid progenitors in the 39° C. cultures also suggested a general stimulatory effect of hyperthermia on the expansion of more primitive stem/progenitor cells and of cells of other lineages.

Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability and enhanced proliferation in culture. Stem cells of the invention retain their plasticity through a higher number of cell passages relative to know methods of stem cell culture. The invention also contemplates the use of such stem cells in the treatment of neurodegenerative disorders including Alzheimer's disease and stroke.

This invention relates to a novel method for growing attenuated mutant Salmonella typhi strains lacking galactose epimerase activity and harboring a recombinant DNA molecule. The method comprises the step of culturing said Salmonella typhi strain without adding glucose to the medium during the fermentation with a starting glucose amount that is depleted before reaching the stationary phase. The invention further relates to attenuated mutant Salmonella typhi strains obtainable by said method and to an attenuated mutant Salmonella typhi strain harboring a recombinant DNA molecule encoding a VEGF receptor protein for use as a vaccine.

The current invention relates to a method of differentiation of human pluripotent stem cells into a human stem-cell derived population of cardiomyocytes. The method comprises the use of specific combination of steps and compounds to induce and/or promote differentiation. The method also comprises steps directed to further maturation of the cardiomyocytes obtained with the method of the invention. Also provided are kits for use in a method of differentiation as well as cell populations obtainable with the method disclosed.

Therapeutic stem cells and methods for their use and manufacture. Stem cells are produced under conditions in which the stem cells are exposed to at least one environmental factor, including decreased oxygen tension. The environmental factors and culture conditions of the invention produce stem cells having an enhanced therapeutic ability and enhanced proliferation in culture. Stem cells of the invention retain their plasticity through a higher number of cell passages relative to know methods of stem cell culture. The invention also contemplates the use of such stem cells in the treatment of neurodegenerative disorders including Alzheimer's disease and stroke.

Abstract: The present invention provides a method of increasing ploidy in cells of a woody perennial plant, the method comprising: contacting plant tissue comprising dividing cells with an effective amount of a composition comprising about 0.5% w/v colchicine to about 3% w/v colchicine. Woody perennial plants with increased ploidy obtained by the method of the invention are also provided.

The present disclosure relates to kidney organoids and methods of manufacturing the same. The organoids and methods may be used in a variety of applications such as disease modelling, drug screening, regenerative medicine and 5 scaling up production of kidney cells.

A syringe is coupled to a biopsy needle through a coupling structure that includes a motor-driven element such as a gear to rotate the needle. The needle can have a sharp beveled tip which, in cooperation with rotation of the needle, harvests tissue in vivo via rotation rather than multiple “sticks” into the patient.

A membrane electrode assembly is constituted of a solid electrolyte membrane 1 made of a polymeric material, and a fuel electrode 2 and an air electrode 3 which are disposed on both sides of the solid electrolyte membrane 1. A porous membrane 8 is attached to the back surface of the fuel electrode 2, and a fuel tank 12 is formed between a casing 16 of the fuel electrode 2 side and the porous membrane 8. The fuel tank 12 is filled with liquid-retaining sheets 14. An air chamber 13 is formed on the back surface of the air electrode 3, and the air chamber 13 is filled with moisture-retaining sheets 15. A casing 17 of the air electrode 3 side is provided with a number of inlet ports 21. Further, fins 22 are formed on an outer surface of the casing 17 of the air electrode side.